Cargando…

Dalbavancin safety in the phase 2/3 clinical development program

Detalles Bibliográficos
Autores principales:	Seltzer, E, Goldberg, L, Krause, D, Simoneau, D, Boudry, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088398/ http://dx.doi.org/10.1186/cc6248

Ejemplares similares

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
por: Minniti, C., et al.
Publicado: (2023)

589. Use of Dalbavancin in Facilitating Discharge of High Risk Patients in Low Resource Settings
por: Milgrom, Alexander
Publicado: (2020)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
por: Simonetti, Oriana, et al.
Publicado: (2021)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009)

1556. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in a self-pay population
por: Murray, E Yancey, et al.
Publicado: (2020)

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
por: Rappo, Urania, et al.
Publicado: (2018)

599. Dalbavancin Utilization in Rural Healthcare Setting: A Single Center Three Years’ Experience
por: AlSalman, Ahmad, et al.
Publicado: (2020)

P02.194. Newly developed functional medicine program in diabetes: impact on clinical and patient reported outcomes - functional medicine and quality of life
por: Franic, D, et al.
Publicado: (2012)

Safety, feasibility and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial
por: Subbiah, Vivek, et al.
Publicado: (2015)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
por: Constantine, Ginger D., et al.
Publicado: (2015)

Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
por: Tong, G, et al.
Publicado: (2013)

A201 EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
por: Travis, S, et al.
Publicado: (2023)

625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder
por: Douglass, Alyse, et al.
Publicado: (2021)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
por: Ruiz-Sancho, Andrés, et al.
Publicado: (2023)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Monetary value and cost analysis of a youth voluntary program on road safety in Iran
por: Seddighi, Hamed, et al.
Publicado: (2019)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie, et al.
Publicado: (2014)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Clinical effect of altered lipid emulsion composition containing fish oil in postoperative patients following abdominal surgery: a prospective, randomized, open-label, comparative, multicenter phase 3 clinical study
por: Keum, M, et al.
Publicado: (2013)

P03.15. Developing a Health Qigong program for children: a 16-week curriculum
por: Wang, C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_eqkvoufoqsbt1nl05pom07v3sl